Innovaderm is Pleased to Announce the Acquisition of Excelsus Statistics
5.7.2022 16:30:00 EEST | Business Wire | Press release
Innovaderm, a leading CRO in dermatology, has expanded its biometrics capacity following the acquisition of Excelsus Statistics, a Montreal-based company specialized in biostatistical and SAS programming services with a special expertise in adaptive trial design, as well as activities in many different therapeutic areas.
“We are pleased to grow our Biometrics team with the addition of new talent,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm has a reputation for excellence in clinical research in dermatology, as well as attracting committed professionals in the field. Our collective expertise will allow us to offer biometrics services across different therapeutic areas and fulfill the growing needs of our clients.”
Since 2014, Excelsus Statistics has served as a collaborator in many studies managed by Innovaderm. The integration of the two companies will allow Excelsus Statistics’ existing clients to now have access to full CRO services including data management in addition to statistical services.
“I am very excited because our experience in statistics and study management coupled with Innovaderm’s international reputation is a win-win situation,” says Diane Potvin, president of Excelsus Statistics. “This is a tremendous opportunity to consolidate resources and drive research forward.”
Innovaderm is a full-service CRO that is known for its excellent in-house data management and biostatistical services. It offers a wide range of biometrics services including protocol design, writing of statistical analysis plans, statistical programming, interpretation and reporting of data for clinical trial reports and publications, and statistical and strategic consulting for product development.
For more information on Innovaderm’s services, visit our website.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005004/en/
Contact information
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABZ Innovation Opens One of Europe's Largest Civilian Drone Manufacturing Facilities17.9.2026 12:43:00 EEST | Press release
ABZ Innovation, a European developer and manufacturer of heavy-duty civilian drones for agricultural and industrial use, today officially opened its new manufacturing facility in Szentendre, Hungary — one of the largest dedicated civilian drone production sites in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917072041/en/ ABZ Innovation's new manufacturing facility in Hungary — one of the largest dedicated civilian drone production sites in Europe. The new facility is approximately four times larger than ABZ Innovation's previous production site, supporting a targeted threefold increase in production during 2026 alone, with a further doubling planned for 2027. This significantly expands ABZ Innovation's capacity to meet accelerating global demand for drone-based automation in agriculture and industry. ABZ Innovation's drone systems are currently deployed in more than 40 countries across six continents, supportin
INSEAD Launches Immersive AI Cases as Its AI-Powered Learning Portfolio Passes 40 Experiences17.9.2026 12:00:00 EEST | Press release
INSEAD, The Business School for the World, today announced two milestones inAI-enabled learning: the commercial launch of its firstImmersive AI Cases via INSEAD Publishing and the expansion of its Immersive Learning portfolio to reach over 40 AI-powered learning experiences in the INSEAD classroom. Together, these developments mark an important milestone in INSEAD’s vision to translate AI-enabled learning into scalable educational offerings for educators and learners worldwide. They also demonstrate the growing adoption of immersive learning across the school and represent a key step in advancing the ambitions of IN:AI, INSEAD’s initiative to harness AI to transform business education and prepare leaders for an AI-enabled world. Francisco Veloso, Dean of INSEAD, said: “The future of management education will not be about choosing between human expertise and AI, but about bringing the two together in ways that deepen learning and strengthen judgement. We are putting this principle into
LTM Honoured with Avasant Digital Masters Award 202617.9.2026 12:00:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that it has been recognized with the Digital Masters Award 2026 in the Innovator category by Avasant, a leading management consulting firm. The award recognizes LTM's commitment to innovation, excellence, and its ability to drive transformative business outcomes for clients through its portfolio of AI-powered offerings. The award was presented during the Digital Masters Awards Ceremony at Partner Connect 2026 in Los Angeles. LTM was among the 18 service providers shortlisted from a field of over 76 global technology service providers assessed by Avasant for this year's Digital Masters Awards. This recognition reflects LTM's strong leadership, domain expertise, and continued contribution to delivering exceptional value for clients globally. "This recognition reflects our focus on helping clients leverage AI to accelerate transformation, create measurable business value, and stay ahead in a rapidly e
IQM to Deliver Its First Quantum Computer in South America to Brazil’s Eldorado Research Institute17.9.2026 10:43:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced a purchase agreement with the Eldorado Research Institute to deploy its first quantum computer in South America, marking IQM's entry into the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917582765/en/ IQM to deliver its first quantum computer in South America to Brazil’s Eldorado Research Institute The IQM Spark quantum computer will be installed at Eldorado's Campinas headquarters, about 100km northwest of São Paulo, in the first quarter of 2027, giving researchers, engineers, universities and industry partners direct access to quantum computers. The agreement also includes remote access to IQM's 54-qubit cloud-based system in Europe, allowing Brazilian teams to develop applications on hardware they own and then move to larger-scale quantum workloads when a problem requires it. “Brazil has the talent, the
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 09:00:00 EEST | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in children and adolescents with neurological conditions, including CP. This condition is associated with muscle tightness that can severely restrict physical movement, daily functioning, and personal autonomy. Among children and youth, CP stands as a primary driver of this symptom and remains the most prevalent childhood motor disability,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom